CHAN YU LING, ABRAHAM - Net Worth and Insider Trading

CHAN YU LING, ABRAHAM Net Worth

The estimated net worth of CHAN YU LING, ABRAHAM is at least $150 Million dollars as of 2024-09-24. CHAN YU LING, ABRAHAM is the 2101 Beneficial owner of PuraPharm Corporation Ltd and owns about 227,119,147 shares of PuraPharm Corporation Ltd (HKSE:01498) stock worth over $150 Million. Details can be seen in CHAN YU LING, ABRAHAM's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that CHAN YU LING, ABRAHAM has not made any transactions after 2023-04-20 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of CHAN YU LING, ABRAHAM

To

CHAN YU LING, ABRAHAM Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, CHAN YU LING, ABRAHAM owns 1 companies in total, including PuraPharm Corporation Ltd (HKSE:01498) .

Click here to see the complete history of CHAN YU LING, ABRAHAM’s form 4 insider trades.

Insider Ownership Summary of CHAN YU LING, ABRAHAM

Ticker Comapny Transaction Date Type of Owner
HKSE:01498 PuraPharm Corporation Ltd 2023-04-20 2101 Beneficial owner

CHAN YU LING, ABRAHAM Latest Holdings Summary

CHAN YU LING, ABRAHAM currently owns a total of 1 stock. CHAN YU LING, ABRAHAM owns 227,119,147 shares of PuraPharm Corporation Ltd (HKSE:01498) as of April 20, 2023, with a value of $150 Million.

Latest Holdings of CHAN YU LING, ABRAHAM

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
HKSE:01498 PuraPharm Corporation Ltd 2023-04-20 227,119,147 0.66 149,898,637

Holding Weightings of CHAN YU LING, ABRAHAM


CHAN YU LING, ABRAHAM Form 4 Trading Tracker

According to the SEC Form 4 filings, CHAN YU LING, ABRAHAM has made a total of 4 transactions in PuraPharm Corporation Ltd (HKSE:01498) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in PuraPharm Corporation Ltd is the acquisition of 20,000 shares on April 20, 2023, which cost CHAN YU LING, ABRAHAM around $21,800.

Insider Trading History of CHAN YU LING, ABRAHAM

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

CHAN YU LING, ABRAHAM Trading Performance

GuruFocus tracks the stock performance after each of CHAN YU LING, ABRAHAM's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by CHAN YU LING, ABRAHAM is -17.7%. GuruFocus also compares CHAN YU LING, ABRAHAM's trading performance to market benchmark return within the same time period. The performance of stocks bought by CHAN YU LING, ABRAHAM within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how CHAN YU LING, ABRAHAM's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of CHAN YU LING, ABRAHAM

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -6.47 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -6.72 LIMIT LIMIT LIMIT LIMIT LIMIT

CHAN YU LING, ABRAHAM Ownership Network

Ownership Network List of CHAN YU LING, ABRAHAM

No Data

Ownership Network Relation of CHAN YU LING, ABRAHAM

Insider Network Chart

CHAN YU LING, ABRAHAM Owned Company Details

What does PuraPharm Corporation Ltd do?

Who are the key executives at PuraPharm Corporation Ltd?

CHAN YU LING, ABRAHAM is the 2101 Beneficial owner of PuraPharm Corporation Ltd. Other key executives at PuraPharm Corporation Ltd include 2202 Interest of your spouse Man Yee Wai, Viola , and 2101 Beneficial owner Fullgold Development Limited .

PuraPharm Corporation Ltd (HKSE:01498) Insider Trades Summary

Over the past 18 months, CHAN YU LING, ABRAHAM made 1 insider transaction in PuraPharm Corporation Ltd (HKSE:01498) with a net purchase of 20,000. Other recent insider transactions involving PuraPharm Corporation Ltd (HKSE:01498) include a net purchase of 20,000 shares made by Man Yee Wai, Viola ,

In summary, during the past 3 months, insiders sold 0 shares of PuraPharm Corporation Ltd (HKSE:01498) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PuraPharm Corporation Ltd (HKSE:01498) were sold and 40,000 shares were bought by its insiders, resulting in a net purchase of 40,000 shares.

PuraPharm Corporation Ltd (HKSE:01498)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

PuraPharm Corporation Ltd Insider Transactions

No Available Data

CHAN YU LING, ABRAHAM Mailing Address

Above is the net worth, insider trading, and ownership report for CHAN YU LING, ABRAHAM. Currently GuruFocus does not have mailing address information for CHAN YU LING, ABRAHAM.

Discussions on CHAN YU LING, ABRAHAM

No discussions yet.